Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

30 September 2024

Alphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China the Company is entitled to receive upfront payment and milestone payments of up to RMB 3.08 billion in total,and is also entitled to receive a double-digit percentage of royalties on net product sales...
16 September 2024

Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024 Both were pooled analysis of two phase I clinical studies of JSKN003 conducted in Australia and China on platinum-resistant ovarian cancer and advanced HER2-positive (IHC 3+) solid tumors.
16 August 2024

Alphamab Oncology Reports 2024 Interim Results and Business Highlights 2024 Interim Results and Business Highlights
12 August 2024

Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024 Onsite Poster display date: Saturday, 14 September 2024
06 June 2024

Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products Alphamab and ArriVent will collaborate to use Alphamab's proprietary linker-payload (Alphatecan) and glycan-conjugation platforms to discover and develop novel ADCs
03 June 2024

Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting JSKN003 exhibited a favorable tolerability and manageable safety profile in heavily pretreated patients with advanced/metastatic solid tumors and demonstrated encouraging antitumor activity during dos...
22 May 2024

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of HER3/TROP2 Bispecific ADC Drug JSKN016 an open-label, multi-center, first-in-human (FIH) phase I clinical trial of JSKN016
06 May 2024

Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting Session Date and Time: 6/1/2024 9:00 AM-12:00 PM CDT
10 April 2024

Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR JSKN003 demonstrated encouraging preliminary antitumor activity in heavily pretreated patients with advanced/metastatic solid tumors
29 March 2024

Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights Alphamab Oncology continued to focus on addressing clinical needs and adhere to differentiated innovation